HVTN 122: A phase 1 double-blind randomized clinical trial to evaluate the safety and immunogenicity of a recombinant oligomeric gp145 clade C Env protein (gp145 C.6980) in healthy HIV-1uninfected adult participants in the US

HVTN 122: A phase 1 double-blind randomized clinical trial to evaluate the safety and immunogenicity of a recombinant oligomeric gp145 clade C Env protein (gp145 C.6980) in healthy HIV-1uninfected adult participants in the US
99 years or below
All
Phase 1
1 Location

Brief description of study

This is a multi-center, randomized, placebo controlled, double blind trial to evaluate the safety and tolerability of 1 injection of gp145 C.6980 at 2 dose levels with alum adjuvant in HIV-seronegative low risk adults.45 healthy, HIV-1uninfected volunteers aged 18 to 50 years: 40 vaccinees, 5 placebo recipients in the US will be enrolled. There are three arms: Group 1 (25) will receive 300 mcg gp145 and Group 2 (15) will receive 100 mcg gp145 and Group 3 (5) will receive placebo.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 828614

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.